Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Opus Genetics, Inc.NASDAQ: IRD
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables falls 42.9% from a year ago
Net receivables stood at $2.72M at the end of Q1 FY2026, down 42.9% from a year earlier and down 14.2% from the prior quarter. Over 3 fiscal years it compounded at -13.3% a year.
Context
- Net receivables amounted to 4.1% of total assets at the end of Q1 FY2026, down 5.8 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -42.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 3.17M USD
- Year-over-year change
- -45.2%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.17M | -45.2% |
| FY2024 | 2024-12-31 | 5.77M | +147.4% |
| FY2023 | 2023-12-31 | 2.33M | -51.9% |
| FY2022 | 2022-12-31 | 4.85M | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 net receivables of $2.72M is the 4th highest of the 10 companies compared; the peer median is $233K.
- Its year-over-year change of -42.9% is the 5th highest of 9, against a peer median of -59.1%.
- Net receivables amounts to 4.1% of total assets for IRD, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $54.06M | +15171.8% | -12.6% | 29.0% | |
| Mar 2026 | $4.26M | -20.5% | -5.3% | 1.6% | |
| Mar 2026 | $3.66M | -23.5% | +39.3% | 10.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $2.72M | -42.9% | -13.3% | 4.1% |
| Mar 2026 | $772K | +105.3% | — | 0.6% | |
| Mar 2026 | $233K | -94.7% | — | 0.2% | |
| Mar 2026 | $28K | -97.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -96.6% | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding IRD) | $233K | -59.1% | -9.0% | 0.2% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.